Literature DB >> 31804864

Trends in the Cost of Cancer Care: Beyond Drugs.

Aaron A Laviana1, Amy N Luckenbaugh1, Matthew J Resnick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31804864      PMCID： PMC6994251          DOI： 10.1200/JCO.19.01963

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  46 in total

1.  What is value in health care?

Authors:  Michael E Porter
Journal:  N Engl J Med       Date:  2010-12-08       Impact factor: 91.245

2.  Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.

Authors:  Aaron A Laviana; Annette M Ilg; Darlene Veruttipong; Hung-Jui Tan; Michael A Burke; Douglas R Niedzwiecki; Patrick A Kupelian; Chris R King; Michael L Steinberg; Chandan R Kundavaram; Mitchell Kamrava; Alan L Kaplan; Andrew K Moriarity; William Hsu; Daniel J A Margolis; Jim C Hu; Christopher S Saigal
Journal:  Cancer       Date:  2015-11-02       Impact factor: 6.860

3.  Early Accountable Care Organization Results in End-of-Life Spending Among Cancer Patients.

Authors:  Miranda B Lam; Jie Zheng; E John Orav; Ashish K Jha
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

4.  Variation in markups on outpatient oncology services in the United States.

Authors:  Angela Park; Tim Xu; Michael Poku; James Taylor; Martin A Makary
Journal:  Am J Manag Care       Date:  2018-02-01       Impact factor: 2.229

5.  Variation in Surgical Outcomes Across Networks of the Highest-Rated US Hospitals.

Authors:  Kyle H Sheetz; Andrew M Ibrahim; Hari Nathan; Justin B Dimick
Journal:  JAMA Surg       Date:  2019-06-01       Impact factor: 14.766

6.  Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery.

Authors:  Tudor Borza; Mary K Oerline; Ted A Skolarus; Edward C Norton; Justin B Dimick; Bruce L Jacobs; Lindsey A Herrel; Chad Ellimoottil; John M Hollingsworth; Andrew M Ryan; David C Miller; Vahakn B Shahinian; Brent K Hollenbeck
Journal:  Ann Surg       Date:  2019-05       Impact factor: 12.969

7.  Medicare Spending after 3 Years of the Medicare Shared Savings Program.

Authors:  J Michael McWilliams; Laura A Hatfield; Bruce E Landon; Pasha Hamed; Michael E Chernew
Journal:  N Engl J Med       Date:  2018-09-05       Impact factor: 91.245

8.  Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?

Authors:  Alexander P Cole; Anna Krasnova; Ashwin Ramaswamy; David F Friedlander; Sean A Fletcher; Maxine Sun; Toni K Choueiri; Joel S Weissman; Adam S Kibel; Quoc-Dien Trinh
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-04-12       Impact factor: 5.554

9.  Regional differences in recommended cancer treatment for the elderly.

Authors:  Vivian Ho; Meei-Hsiang Ku-Goto; Hui Zhao; Karen E Hoffman; Benjamin D Smith; Sharon H Giordano
Journal:  BMC Health Serv Res       Date:  2016-07-15       Impact factor: 2.655

10.  Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening.

Authors:  Matthew J Resnick; Amy J Graves; Sunita Thapa; Robert Gambrel; Mark D Tyson; Daniel Lee; Melinda B Buntin; David F Penson
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873
View more
  4 in total

1.  Weighing Costs and Benefits in the Economics of Cancer Care.

Authors:  Scott D Ramsey; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

2.  Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.

Authors:  Eric J Chow; David R Doody; Jennifer J Wilkes; Laura K Becker; Shasank Chennupati; Pamela E Morin; Lena E Winestone; Henry J Henk; Gary H Lyman
Journal:  Leuk Lymphoma       Date:  2020-12-07

3.  Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.

Authors:  Ruijia Chen; Yalan Zhang; Kongying Lin; Defu Huang; MaoJin You; Yanjin Lai; Jinye Wang; Yingying Hu; Na Li
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

4.  Differences in Cancer Care Expenditures and Utilization for Surgery by Hospital Type Among Patients With Private Insurance.

Authors:  Samuel U Takvorian; Laura Yasaitis; Manqing Liu; Daniel J Lee; Rachel M Werner; Justin E Bekelman
Journal:  JAMA Netw Open       Date:  2021-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.